Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like MilliporeSigma Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes May 14, 2017 <b>Hip Innovation Technology</b> Initiates Clinical Trial Of Its Novel Hip Replacement System For The Treatment Of Total Hip Arthroplasty August 8, 2017 Rumor Alert: AstraZeneca PLC CEO to Become Teva's New Leader July 12, 2017
MilliporeSigma Launches Industry's First Off-the-Shelf Cell Culture Media for Perfusion Processes May 14, 2017
<b>Hip Innovation Technology</b> Initiates Clinical Trial Of Its Novel Hip Replacement System For The Treatment Of Total Hip Arthroplasty August 8, 2017
